Literature DB >> 8162643

Cytokine concentrations in the synovial fluid and plasma of rheumatoid arthritis patients: correlation with bony erosions.

K Y Fong1, M L Boey, W H Koh, P H Feng.   

Abstract

Cytokines are important protein mediators in inflammatory joint diseases. The synovial fluid and plasma concentrations of interleukin-1 alpha (IL-1 alpha), interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-alpha), interferon-alpha (IF-alpha) and interferon-gamma (IF-gamma) were measured by RIA and ELISA in 28 rheumatoid arthritis (RA) patients (5 males and 23 females). Ten patients with knee effusions due to other causes (osteoarthritis, psoriasis, gout, rheumatic fever, systemic lupus erythematosus) were also studied. Eight of the RA patients had erosive disease. The synovial fluid IL-1 alpha and IL-2 concentrations were higher in Group 1 (erosive) [IL-1 alpha: 524 pg/ml (SEM: 127), IL-2: 3.28 ng/ml (SEM: 1.0)] than in either Group 2 (non-erosive) [IL-1 alpha: 241 pg/ml (SEM: 24), IL-2: 1.93 ng/ml (SEM: 0.6)] or Group 3 (non-RA) [IL-1 alpha: 267 pg/ml (SEM: 58), IL-2: 0.35 ng/ml (SEM: 0.6)] (p < 0.003 and p < 0.06 respectively). Plasma IL-1 and IL-2 levels were higher in Group 1 [IL-1 alpha: 408 pg/ml (SEM: 107), IL-2: 4.20 ng/ml (SEM: 1.5)] than in Group 2 [IL-1 alpha 150 pg/ml (SEM: 15), IL-2: 2.58 ng/ml (SEM: 0.7)] or Group 3 [IL-1 alpha: 140 pg/ml (SEM: 11), IL-2: 1.93 ng/ml (SEM: 0.3)] (p < 0.01, p < 0.009 respectively). There were no differences in the IFN-alpha, IFN-gamma or TNF-alpha levels between groups. These findings suggest that plasma cytokines levels may reflect synovial levels and that IL-1 alpha may play a significant role in erosive joint disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8162643

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  8 in total

Review 1.  Synovial perfusion and synovial fluid solutes.

Authors:  P A Simkin
Journal:  Ann Rheum Dis       Date:  1995-05       Impact factor: 19.103

2.  A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.

Authors:  S B Cohen; L W Moreland; J J Cush; M W Greenwald; S Block; W J Shergy; P S Hanrahan; M M Kraishi; A Patel; G Sun; M B Bear
Journal:  Ann Rheum Dis       Date:  2004-04-13       Impact factor: 19.103

3.  Multiple interleukin-1beta-converting enzymes contribute to inflammatory arthritis.

Authors:  Christian Stehlik
Journal:  Arthritis Rheum       Date:  2009-12

4.  Synovial fluid concentrations and relative potency of interleukin-1 alpha and beta in cartilage and meniscus degradation.

Authors:  Amy L McNulty; Nicole E Rothfusz; Holly A Leddy; Farshid Guilak
Journal:  J Orthop Res       Date:  2013-03-11       Impact factor: 3.494

5.  Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor alpha in the knee-joints of patients with rheumatoid arthritis.

Authors:  J Neidel; M Schulze; J Lindschau
Journal:  Inflamm Res       Date:  1995-05       Impact factor: 4.575

6.  [Psoriasis und Psoriasis arthritis in childhood and adolescence. Overview and consensus statement of the 9th Wörlitz Expert Round Table Discussion 2006 for the Society for Child and Adolescent Rheumatology].

Authors:  M Sticherling; K Minden; R-M Küster; A Krause; M Borte
Journal:  Z Rheumatol       Date:  2007-07       Impact factor: 1.372

Review 7.  Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation.

Authors:  J B Weinberg
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

8.  Inhibitory effect of Astragalus polysaccharides on lipopolysaccharide-induced TNF-a and IL-1β production in THP-1 cells.

Authors:  Xiaojuan He; Jun Shu; Li Xu; Cheng Lu; Aiping Lu
Journal:  Molecules       Date:  2012-03-12       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.